Indivior signs off as a standalone company with a fifth straight EPS beat
As seen on the 24/7 Wall St. homepage on October 29, 2026.
This is the last quarter Indivior reports as a standalone company, and it went out with a fifth straight EPS beat, again exceeding expectations. The Supernus merger closes November 2, with shares trading under the new symbol the next day.
Continue ReadingShow less
Indivior posted adjusted non-GAAP EPS of $1.32 for Q3 2026, beating expectations for the fifth consecutive quarter in its final standalone result.
SUBLOCADE, Indivior's long-acting injectable buprenorphine treatment, drove the quarter with $267 million in net revenue, up 22% from a year ago.
Margins widened alongside the top-line gains, with adjusted EBITDA up 76% to $211 million as cost of sales and R&D expense both fell.
Sponsored
Management reaffirmed standalone full-year 2026 guidance, though that outlook lapses when the all-stock merger with Supernus Pharmaceuticals closes November 2, 2026, after which the combined company trades on Nasdaq as SUPN beginning November 3.
CEO Joe Ciaffoni framed the quarter as a conclusion: "Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda." Investors now own the combined CNS-focused entity's ability to sustain the growth SUBLOCADE built.
Mentioned: INDV